{"id":"esketamine-nasal-product","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Dissociation"},{"rate":"25-40","effect":"Dizziness"},{"rate":"20-35","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"15-25","effect":"Sedation"},{"rate":"10-20","effect":"Vertigo"}]},"_chembl":{"chemblId":"CHEMBL2364609","moleculeType":"Small molecule","molecularWeight":"274.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Esketamine is the S-enantiomer of ketamine and works by antagonizing N-methyl-D-aspartate (NMDA) receptors, which are glutamate-gated ion channels. This blockade leads to rapid disinhibition of downstream neural circuits and increased synaptic plasticity, resulting in antidepressant effects that occur within hours to days rather than weeks. The nasal formulation allows for non-invasive systemic delivery while potentially achieving rapid CNS penetration.","oneSentence":"Esketamine is an NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce fast-acting antidepressant effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:22.339Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"},{"name":"Major depressive disorder with acute suicidal ideation or behavior"}]},"trialDetails":[{"nctId":"NCT06726382","phase":"PHASE1","title":"KF2024#1-trial: Esketamine Interaction Study","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2024-12-09","conditions":"Drug Interactions, Food-drug Interaction","enrollment":12},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05973851","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2024-08-31","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":418},{"nctId":"NCT04829318","phase":"PHASE4","title":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2021-04-26","conditions":"Depressive Disorder, Major","enrollment":183},{"nctId":"NCT04338321","phase":"PHASE3","title":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2020-08-21","conditions":"Depressive Disorder, Major","enrollment":676},{"nctId":"NCT05268497","phase":"PHASE1","title":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-01","conditions":"Depression","enrollment":""},{"nctId":"NCT06051227","phase":"PHASE3","title":"Fentanyl or Esketamine for Traumatic PAIN (FORE-PAIN) Trial","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2024-01-11","conditions":"Acute Pain Due to Trauma, Analgesia, Fentanyl","enrollment":608},{"nctId":"NCT04843462","phase":"NA","title":"Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray","status":"UNKNOWN","sponsor":"Lukas Pezawas","startDate":"2021-04-29","conditions":"Major Depressive Disorder, Therapy Resistant Depression","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ATC code: N06AB10"],"phase":"phase_3","status":"active","brandName":"Esketamine Nasal Product","genericName":"Esketamine Nasal Product","companyName":"Dr. Inge Winter","companyId":"dr-inge-winter","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esketamine is an NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce fast-acting antidepressant effects. Used for Treatment-resistant depression, Major depressive disorder with acute suicidal ideation or behavior.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}